A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409
Recruiting
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smalle... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: UCLA ( Site 0317), Los Angeles, California +54 locations
Conditions: Colorectal Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2025
Locations: Cullman Clinical Trials, Cullman, Alabama +40 locations
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Comparing AI Role-Play and Peer Role-Play for Informed Consent Training in Endoscopy: A Randomized Control Trial
NCT07069504
Recruiting
The goal of this randomized controlled trial is to find out whether AI-based role play is effective in teaching healthcare trainees how to obtain informed consent from patients for endoscopic procedures. The main question is: • How does generative AI-based role play compare to traditional peer role play in training healthcare trainees to deliver informed consent for endoscopic procedures? Researchers will compare AI-based role play with peer role play to see which method is more effective for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Scarborough Health Network, University of Toronto, Toronto, Ontario
Conditions: Informed Consent Process
Register for Updates
The Active Transition Home Post-Stroke Program
NCT06119230
Recruiting
Post-stroke participants will wear wearable sensors for one week at 1-week prior to discharge from inpatient rehabilitation, 3- and 7- weeks post-discharge and 3-months post-discharge. All participants will wear sensors but only participants in the intervention group will receive sensor-informed activity feedback (e.g., activity, sleep and sedentary behaviour) and feedback informed goal setting sessions with a physiotherapist. The feedback forms will be co-created with physiotherapists working a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: GF Strong Rehabilitation Centre, Vancouver, British Columbia
Conditions: Stroke
Register for Updates
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814
Recruiting
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Research Site, Fayetteville, Arkansas +287 locations
Conditions: Metastatic Non-small Cell Lung Cancer
Register for Updates
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176
Recruiting
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the ef... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Phoenix Childrens Hospital, Phoenix, Arizona +78 locations
Conditions: Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Register for Updates
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02.
Gender:
ALL
Ages:
Between 25 years and 70 years
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Edmonton, Not set +15 locations
Conditions: Huntington's Disease
Register for Updates
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
NCT06368245
Recruiting
This is a multicenter retrospective comparative cohort study. The index surgery for this study is primary or revision long-segment posterior thoracolumbar (TL) instrumented fusion using either a supplementary rod construct or a dual-rod construct. Eligible patients who already had index surgery, will be identified for enrollment through a review of medical records of the participating surgeons at the study sites.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/15/2025
Locations: Stanford Spine Clinic, Redwood City, California +15 locations
Conditions: Spinal Fusion
Register for Updates
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
NCT07006792
Recruiting
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology, Birmingham, Alabama +74 locations
Conditions: Atopic Dermatitis
Register for Updates
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: eStudySite, La Mesa, California +49 locations
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Register for Updates
Low INR to Minimize Bleeding With Mechanical Valves Trial
NCT03636295
Recruiting
This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Ziekenhuis Oost-Limburg, Genk, Limburg +25 locations
Conditions: Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement
Register for Updates
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712
Recruiting
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional saf... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Sacramento, California +38 locations
Conditions: Cerebral Amyloid Angiopathy
Register for Updates